Retatrutide is an investigational medication being studied for obesity, overweight, and related metabolic conditions.
Unlike currently approved GLP-1 medications, retatrutide is designed to activate three hormone receptors:
GLP-1
GIP
Glucagon
Retatrutide is being studied as a once-weekly subcutaneous injection in clinical trials.
The clinical-trial doses and schedules should not be presented as recommended dosing for patients outside an authorized clinical trial.
Retatrutide is an investigational medication being studied for obesity, overweight, and related metabolic conditions.
Unlike currently approved GLP-1 medications, retatrutide is designed to activate three hormone receptors:
GLP-1
GIP
Glucagon
Retatrutide is being studied as a once-weekly subcutaneous injection in clinical trials.
The clinical-trial doses and schedules should not be presented as recommended dosing for patients outside an authorized clinical trial.
